Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the I-Plastin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Abstract: The present invention relates to a monoclonal antibody capable of binding to a wild-type HBsAg antigen and to at least one, preferably at least two and advantageously more than two, mutant forms of the HBsAg antigen, said monoclonal antibody binding to a peptide sequence consisting of at least 6 contiguous amino acids in the 199-208 region of the HBsAg antigen, and advantageously binding to the peptide sequence constituted by the 199-208 region of the HBsAg antigen.

Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the I-Plastin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Abstract: The invention relates to an isolated cytotoxic factor which is associated with multiple sclerosis and which is selected from the heterocomplex GM2AP/GM2/MRP14 and mutated GM2AP/GM2/MRP14, and to the method of detecting said factor in a biological sample to be tested. The inventive method comprises the following steps consisting in: (i) bringing the biological sample into contact with at least one capture antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and with at least one labeled detection antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and (ii) detecting and/or quantifying the cytotoxic factor by detecting and/or quantifying the labeled detection antibody.

Abstract: The invention relates to an isolated cytotoxic factor which is associated with multiple sclerosis and which is selected from the heterocomplex GM2AP/GM2/MRP14 and mutated GM2AP/GM2/MRP14, and to the method of detecting said factor in a biological sample to be tested. The inventive method comprises the following steps consisting in: (i) bringing the biological sample into contact with at least one capture antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and with at least one labeled detection antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and (ii) detecting and/or quantifying the cytotoxic factor by detecting and/or quantifying the labeled detection antibody.

Abstract: The invention concerns a monoclonal antibody capable of binding with a wild type HBsAg antigen and with at least one, preferably at least two and advantageously more than two, mutated forms of the HBsAg antigen, the monoclonal antibody binding with the peptide sequence consisting of at least 6 adjacent amino acids in the 199-208 region of the HBsAg antigen, and advantageously binding with the peptide sequence formed by the 199-208 region of the HbsAg antigen.

Abstract: The invention concerns a saturated or unsaturated abietane derivative of general formula (I) wherein: Z is selected among —COOR5, —CONR1R2, —COONR3R4, —COR6, —CON, —COOR5, —CHOHR7, —SR8, —OR8, —CN, —CNO, —CNS, —NCO, —NCS and —R1R2CR9; wherein R1, R2, R3 and R4 represent a hydrogen atom, a C1-C10 alkyl, a C6-C20 aryl optionally substituted, a C7-C10 alkene, a C1-C10 alkyne, or an aminoacyl or peptidyl optionally substituted; or R1 and R2 or R3 and R4 together form a cycle or a heterocycle; R5 represents a hydrogen, a C1-C10 alkyl, a C1-C10 alkene, a C1-C10 alkyne, or an aryl optionally substituted into C6-C20; R6 represents a hydrogen, a halogen, a C1-C10 alkyl, a C1-C10 alkene, a C1-C10 alkyne, or an aryl optionally substituted into C6-C20; R7 represents a hydrogen, a C1-C10 alkyl, a C1-C10 alkene, or a C1-C10 alkyne; R8 represents a hydrogen, a C1-C10 alkyl, a C1-C10 alkene, or a C1-C10 alkyne; and R9 is selected among

Abstract: A monoclonal or polyclonal antibody specific for an epitope common to Staphylococcus aureus strains of various capsular serotypes, particularly methicillin-resistant strains, the antibody being selected from immunoglobulins G, M, and A, and the use thereof in a reagent for detecting Staphylococcus aureus.

Abstract: Method of assaying hapten in a sample, in which said sample is placed in contact with antibodies capable of recognizing hapten and with a predetermined quantity of a reagent capable of competing with said hapten-fixing antibodies. The reagent is a conjugate formed by a single-stranded fragment of nucleic acid with a compound capable of being recognized by said hapten-recognizing antibodies. The fixed or unfixed reactant is detected by antibodies capable of recognizing the nucleic acid fragment of said conjugate. Detection of said reactant by anti-fragment antibodies of said nucleic acid enhances, in particular, the sensitivity of the assay.

Abstract: A device for assaying haptens includes a solid support linked through a nucleic acid fragment to a reagent that can compete with the hapten for binding to antibodies that bind to the hapten. A process for assaying a hapten uses this device.